EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

First-line biologic therapy selection highly impacts ulcerative colitis outcomes: results from the APPETISER study

Diari M'Baye, Marianne Hupé, Marie Dodel, Maëva Bazoge, Bruno Pereira, Anthony Buisson

Intestinal Research · 31.10.2026 · 24 (4) · 757-766

DOI: 10.5217/ir.2025.00125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Intestinal Research, erschienen am 31.10.2026. Verfasst von Diari M'Baye und 5 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Hépato-Gastroentérologie, CHU Clermont-Ferrand, Inserm, 3iHP, Université Clermont Auvergne, Clermont-Ferrand, France. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: We compared the effectiveness of 2 strategies based on the choice of the first biologic owing to either drug efficacy or better acceptability in patients with ulcerative colitis (UC).

Methods

We collected real-world data of all consecutive UC patients ≥ 18 years starting a first line of biologic for active UC with follow-up > 6 months. Patients were considered as receiving either an effectiveness-based strategy (EBS) if they started with infliximab or vedolizumab, or acceptability-based strategy (ABS) if they started with adalimumab or golimumab. Corticosteroid-free clinical remission (PRO2-CFREM) was defined as the absence of bleeding, normalization of stool frequency and no steroid assessed as a binary criterion each month. All comparisons were adjusted using propensity scores.

Results

Overall, 130 patients and 3,355 months were analyzed. The percentage of months spent in PRO2-CFREM within the first 24 months (primary endpoint) was greater in EBS arm than in ABS arm (74.2% vs. 46.6%; P< 0.001), was higher within the first 6 months (60.4% vs. 18.9%), and was not rescued later between months 7 and 12 (73.1% vs. 38.6%), months 13 and 18 (79.9% vs. 57.0%) or M19 and M24 (83.3% vs. 64.6%) (P< 0.001 for all comparisons). EBS group had a lower risk to first-line biologic discontinuation (adjusted hazard ratio [aHR], 6.5; 95% confidence interval [CI], 2.8–15.3: P< 0.001) and a trend for lower risk of colectomy (aHR, 4.5; 95% CI, 0.9–22.3; P= 0.068).

Conclusions

The choice of first-line biologic is highly impacting UC outcome and cannot be fully compensated by later treatments, advocating for the use of the most effective therapeutic option as first-line biologic.

Schlagwörter

Stichwörter der Autor:innen

Bio-naïve patientsBiological productsInflammatory bowel diseasesTherapeutic sequencingUlcerative colitis

Autor:innen und Institutionen

  • Service d'Hépato-Gastroentérologie, CHU Clermont-Ferrand, Inserm, 3iHP, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Hepato-Gastroenterology and Digestive Oncology Department, CHU Grenoble Alpes, Institute for Advanced Biosciences, CNRS UMR 5309-INSERM U1209, Université Grenoble Alpes, Grenoble, France.
  • DRCI, Unité de Biostatistiques, CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Service d'Hépato-Gastroentérologie, CHU Clermont-Ferrand, Inserm, 3iHP, Université Clermont Auvergne, Clermont-Ferrand, France. a_buisson@chu-clermontferrand.fr.
  • Inserm U1071, M2iSH, USC-INRA 2018, F-63000, Université Clermont Auvergne, Clermont-Ferrand, France. a_buisson@chu-clermontferrand.fr.

Zitieren

APA

M'Baye, D., Hupé, M., Dodel, M., Bazoge, M., Pereira, B., & Buisson, A. (2026). First-line biologic therapy selection highly impacts ulcerative colitis outcomes: results from the APPETISER study. Intestinal Research, 24(4), 757-766. https://doi.org/10.5217/ir.2025.00125

Vancouver

M'Baye D, Hupé M, Dodel M, Bazoge M, Pereira B, Buisson A. First-line biologic therapy selection highly impacts ulcerative colitis outcomes: results from the APPETISER study. Intestinal Research. 2026;24(4):757-766. doi:10.5217/ir.2025.00125

BibTeX
@article{MBaye2026,
  author = {M'Baye, Diari and Hupé, Marianne and Dodel, Marie and Bazoge, Maëva and Pereira, Bruno and Buisson, Anthony},
  title = {First-line biologic therapy selection highly impacts ulcerative colitis outcomes: results from the APPETISER study},
  journal = {Intestinal Research},
  year = {2026},
  volume = {24},
  number = {4},
  pages = {757--766},
  doi = {10.5217/ir.2025.00125}
}
Kostenlos starten →